Position in NVO
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$29,458,285
+$420,510 QoQ
Shares Held
801,586
+40.5% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
1.92%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026SMITH CHAS P & ASSOCIATES PA CPAS holds $179,997,284 across 8 Drug Manufacturers - General names. NVO ranks #4 (16.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
251,939 | $61,583,969 | |
| 2 | MRK |
Merck & Co., Inc.
|
367,523 | $44,209,341 | |
| 3 | AMGN |
Amgen Inc
|
118,985 | $41,864,872 | |
| 4 | NVO |
Novo Nordisk A S
This page
|
801,586 | $29,458,285 | |
| 5 | LLY |
ELI LILLY & Co
|
1,254 | $1,153,391 | |
| 6 | ABBV |
AbbVie Inc.
|
4,249 | $924,115 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
7,023 | $425,944 | |
| 8 | PFE |
Pfizer Inc
|
13,439 | $377,367 |
All Filings in NVO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,458,285 | 801,586 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $29,037,775 | 570,711 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $22,497,033 | 405,425 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $13,629,103 | 197,466 | Shares | Sole | 2025-07-17 | |
| 2025-03-31 | $5,628,320 | 81,053 | Shares | Sole | 2025-05-08 | |
| No filing history on record for this holder in this stock. | ||||||